Premium
O4‐01‐02: Tau and Amyloid Pet Imaging in a Colombian Kindred with Autosomal‐Dominant Alzheimer's Disease
Author(s) -
Quiroz Yakeel T.,
Sperling Reisa A.,
Baena Ana,
Arboleda-Velasquez Joseph,
Schultz Aaron P.,
Cosio Danielle M.,
LaPoint Molly R.,
Judge Kelly,
Jaimes Sehily Y.,
Norton Daniel J.,
Reiman Eric M.,
Lopera Francisco,
Johnson Keith
Publication year - 2016
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2016.06.607
Subject(s) - entorhinal cortex , asymptomatic carrier , temporal lobe , psen1 , amyloid (mycology) , pathology , cerebellar cortex , neuroscience , dementia , medicine , alzheimer's disease , hippocampus , cerebellum , psychology , asymptomatic , disease , presenilin , epilepsy
tangle (NFT)-tau pathology can be present in patients with probable dementia with Lewy bodies (DLB). The extent and distribution of NFT-tau pathology and the association of NFT-tau deposition with amyloid-beta deposition in patients with probable DLB is unknown. Our objective was to determine the pattern of AV-1451 uptake in patients with probable DLB, and its relationship to amyloidbeta deposition on PET. Methods: We recruited probable DLB (n1⁄412) patients from the Mayo Clinic ADRC, who underwent MRI, AV-1451 and C11-Pittsburgh compound B (PiB) PET examinations. An age and sex matched cohort of Alzheimer’s disease dementia (AD) (n1⁄49) and clinically normal (CN) subjects (n1⁄461) were identified. To be included CN subjects had to have a negative PiB PET scan with global PiB standardized volume uptake ratio (SUVR) <1.4. Regional AV-1451 uptake was measured by co-registering PET images to MRI and segmenting gray matter regions using an in-house atlas. AV-1451 PET voxels were normalized to the cerebellar uptake and voxel-based analyses were performed on SPM correcting for family-wise error. Results: Patients with AD dementia had significantly higher AV-1451 uptake than probable DLB particularly in the temporal, frontal and parietal limbic and association cortices. Patients with DLB had increased AV-1451 uptake in the inferior temporal, angular, and superior parietal gyri, occipital lobe and precuneus compared to CN both on voxelbased and atlas-based analysis (p<0.05). (Figure) We combined the AV-1451 uptake in these regions that had higher AV-1451 uptake in probable DLB than CN (meta-ROI). No association was found between the median AV-1451 SUVR in the meta-ROI and the global PiB PET SUVR in patients with DLB (r1⁄40.08; p1⁄40.82). Conclusions:AD dementia patients have substantially higher AV-1451 uptake than probable DLB patients, which clearly distinguishes the two dementia syndromes. In patients with probable DLB, AV-1451 uptake was higher in the temporal, parietal and occipital association cortices compared to CN, however this was not related to the amyloid-beta deposition. This posterior temporoparietal and occipital pattern of AV-1451 uptake resembles the pattern of hypometabolism in DLB, which requires further investigation. O4-01-02 TAU AND AMYLOID PET IMAGING IN A COLOMBIAN KINDREDWITH AUTOSOMALDOMINANTALZHEIMER’S DISEASE Yakeel T. Quiroz, Reisa A. Sperling, Ana Baena, Joseph ArboledaVelasquez, Aaron P. Schultz, Danielle M. Cosio, Molly R. LaPoint, Kelly Judge, Sehily Y. Jaimes, Daniel J. Norton, Eric M. Reiman, Francisco Lopera, Keith Johnson, Grupo de Neurociencias, Universidad de Antioquia, Medellin, Colombia; Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA; Center for Alzheimer Research and Treatment, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA; 4 Athinoula A. Martinos Center for Biomedical Imaging,Massachusetts General Hospital, HarvardMedical School, Charlestown, MA, USA; Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA; 6 Schepens Eye Research Institute, Boston, MA, USA; 7 Massachusetts General Hospital, Charlestown, MA, USA; University of Arizona, Tucson, AZ, USA; Banner Alzheimer’s Institute, Phoenix, AZ, USA; Department of Radiology, Division of Molecular Imaging and Nuclear Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA; Athinoula A. Martinos Center for Biomedical Imaging and the Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, USA. Contact e-mail: yquiroz@mgh. harvard.edu